These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1462165)

  • 21. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB; Tuszynski JA; Klobukowski M
    J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.
    Rahmani R; Guéritte F; Martin M; Just S; Cano JP; Barbet J
    Cancer Chemother Pharmacol; 1986; 16(3):223-8. PubMed ID: 3698163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
    Zamora JM; Pearce HL; Beck WT
    Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vinca-23-oyl amino acid derivatives: as new anticancer agents (review).
    Bhushana Rao KS; Collard MP; Trouet A
    Anticancer Res; 1985; 5(4):379-86. PubMed ID: 3898995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.
    Montag G; Stopper H; Ngo QA; Hintzsche H
    Curr Cancer Drug Targets; 2019; 19(3):222-230. PubMed ID: 29714145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in vinca-alkaloids: Navelbine.
    Marty M; Extra JM; Espie M; Leandri S; Besenval M; Krikorian A
    Nouv Rev Fr Hematol (1978); 1989; 31(2):77-84. PubMed ID: 2671933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
    Coltman CA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vinorelbine treatment IND program announced.
    Am J Hosp Pharm; 1994 Sep; 51(17):2087. PubMed ID: 7755700
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts.
    Hendriks HR; Langdon S; Berger DP; Breistøl K; Fiebig HH; Fodstad O; Schwartsmann G
    Eur J Cancer; 1992; 28A(4-5):767-73. PubMed ID: 1524896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids.
    Rowinsky EK
    Curr Opin Oncol; 1991 Dec; 3(6):1060-9. PubMed ID: 1843108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Towards bioproduction of anticancer drugs by yeast].
    Courdavault V; Papon N; Clastre M
    Med Sci (Paris); 2019 May; 35(5):417-419. PubMed ID: 31115322
    [No Abstract]   [Full Text] [Related]  

  • 33. The vinca alkaloids.
    O'Marcaigh AS; Betcher DL
    J Pediatr Oncol Nurs; 1995 Jul; 12(3):140-2. PubMed ID: 7646834
    [No Abstract]   [Full Text] [Related]  

  • 34. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
    Chi S; Xie W; Zhang J; Xu S
    J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A summary of vinorelbine (Navelbine) safety data from North American clinical trials.
    Hohneker JA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):42-6; discussion 46-7. PubMed ID: 7973769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.
    Brogden JM; Nevidjon B
    Oncol Nurs Forum; 1995 May; 22(4):635-46. PubMed ID: 7675666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactivity of vinca alkaloids during water chlorination processes: Identification of their disinfection by-products by high-resolution quadrupole-Orbitrap mass spectrometry.
    Negreira N; Regueiro J; López de Alda M; Barceló D
    Sci Total Environ; 2016 Feb; 544():635-44. PubMed ID: 26674693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and SAR of vinca alkaloid analogues.
    Voss ME; Ralph JM; Xie D; Manning DD; Chen X; Frank AJ; Leyhane AJ; Liu L; Stevens JM; Budde C; Surman MD; Friedrich T; Peace D; Scott IL; Wolf M; Johnson R
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1245-9. PubMed ID: 19147348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.